Lida Pacaud

VP, Clinical Development at Legend Biotech


Dr. Lida Pacaud joined Legend Biotech as the Vice President of Clinical Development in January, 2021. Most recently, Lida served as the Global Clinical Program Head and Executive Medical Director in Cell & Gene unit at Novartis. Prior to that, Lida worked at Roche and Wyeth. She has been the Medical Lead on several Phase I, II & III trials, including 3 major regulatory submissions to the FDA, EMA and other worldwide health authorities for KYMRIAH®, AFINITOR® and AVASTIN®. Lida has covered programs in breast cancer, brain tumors, sarcomas, Gastrointestinal and lung neuroendocrine tumors, diffuse large B-cell lymphoma, follicular lymphoma, and acute lymphoblastic leukemia. In her role in Cell & Gene unit in Novartis, Lida led clinical development and filling of KYMRIAH, first approved CART therapy worldwide that was also awarded the esteemed Prix Galien USA Award for Best Biotechnology Product in 2018. On this program, Lida led US breakthrough therapy designation and EU PRIME designation for DLBCL, as well as Regenerative Medicine Advanced Therapy (RMAT) designation for follicular lymphoma, and she oversaw large global cross-functional clinical teams up to 100 individuals. Lida has also experience in BD&L activities as clinical evaluator of external cell therapy opportunities.

Dr. Lida Pacaud holds a Doctor of Medicine degree and certification in Pediatrics from Tbilisi State Medical University and has trained in Pediatric Oncology and hematology in France.


  • VP, Clinical Development

    Current role

View in org chart

The Org
helps you hire
great candidates
It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.